COMMUNIQUÉ DE PRESSE
News
-
-
-
-
COMMUNIQUÉ DE PRESSE
EQS-Adhoc: creditshelf Aktiengesellschaft: ORDER FOR START OF PROTECTIVE SHIELD PROCEEDINGS
creditshelf Aktiengesellschaft has obtained a court order to start protective shield proceedings, appointing a provisional trustee and general representative for restructuring in self-administration -
COMMUNIQUÉ DE PRESSE
Original-Research: GBC Insider Focus Index (von GBC AG): Indexanpassung
GBC Insider Focus Index verzeichnet Indexanpassung mit aktuellen Insiderkäufen, Director’s Dealings dienen als Indikator für Marktbewegungen und Zukunftsaussichten. Indexperformance: +51,29% seit Start am 19.09.2016, geringe Volatilität im Vergleich zu Referenzindizes -
COMMUNIQUÉ DE PRESSE
AutoNetTV Studios Named Preferred Agency Vendor for SEMA Data
AutoNetTV Studios, an automotive content creation and photography agency, has been named a Preferred Vendor for SEMA Data, offering specially negotiated pricing for product photography, video production, and marketing materials creation -
-
COMMUNIQUÉ DE PRESSE
TruLab Integration to Florence Streamlines Biospecimen Data Management for Clinical Sites
TruLab and Florence Healthcare announce a technology partnership to provide a single solution for biospecimen and protocol data storage. The integrated platform will reduce lab queries, eliminate manual data entry, and provide centralized monitoring of protocol exceptions -
COMMUNIQUÉ DE PRESSE
TuHURA Biosciences, Inc. Appoints Dennis Yamashita, Ph.D., as Chief Scientific Officer and Head of Discovery Research and Early Development
TuHURA Biosciences, Inc. appoints Dr. Dennis Yamashita as Chief Scientific Officer and Head of Discovery Research and Early Development to advance novel personalized cancer vaccines and bi-functional antibody drug conjugates. Dr. Yamashita brings over 30 years of experience in R&D drug discovery and development -
COMMUNIQUÉ DE PRESSE
Cloud DX Receives $770,000 Order for New Technology Devices and Services
Cloud DX (TSXV:CDX)(OTCQB:CDXFF) receives a purchase order for up to 300 Vitaliti™ Continuous Vital Sign Monitor Systems and related software valued at approximately $770,000 CAD. The order, including a 50% deposit, is expected to be delivered by the end of Q2 2024 for a groundbreaking multi-site academic study of post-surgical patients
